AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Positive Studiendaten zu COPD-Medikament: Leerink hebt Kursziel für AstraZeneca auf 220 US-Dollar an
Investing.com - Leerink Partners hat sein Kursziel für die Aktie von AstraZeneca (NASDAQ:AZN) von 219 US-Dollar auf 220 US-Dollar angehoben und die Einstufung auf "Outperform" belassen. Grund hierfür ...
CAMBRIDGE, UK – AstraZeneca (LSE/STO/NYSE:AZN) gab am Donnerstag in einer Pressemitteilung bekannt, dass der Wirkstoff Tozorakimab in Two Phase-III-Studien zur Behandlung der chronisch-obstruktiven ...
Berlin. Die aktualisierte S2k-Leitlinie „Fachärztliche Diagnostik und Therapie der COPD“ dient als Ergänzung der Nationalen Versorgungsleitlinie COPD, die zuletzt im Jahr 2021 erschienen ist. Seither ...
In Deutschland schreiben nach Angaben der Deutschen Krankenhausgesellschaft 80 Prozent der Krankenhäuser rote Zahlen. Verluste müssen teils durch die öffentliche Hand ausgeglichen werden. DKG-Chef Gaß ...
The therapeutic variations among patients with chronic obstructive pulmonary disease (COPD) present ongoing treatment challenges. However, the two currently approved biologics, dupilumab and ...
Chronic obstructive pulmonary disease, or COPD, is often thought of as a condition that only affects longtime smokers. In reality, the disease reaches far beyond that group. Women are ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.
Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management. COPD encompasses both extremes of weight. Obesity affects some 54% of patients in the U.S.
Scientists have discovered that people with COPD have lung cells that contain over three times as much soot-like carbon as those of smokers without the disease. These overloaded cells are larger and ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results